These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

697 related articles for article (PubMed ID: 21074069)

  • 21. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations.
    Camacho LH
    Cancer Med; 2015 May; 4(5):661-72. PubMed ID: 25619164
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Update on the role of ipilimumab in melanoma and first data on new combination therapies.
    Maio M; Di Giacomo AM; Robert C; Eggermont AM
    Curr Opin Oncol; 2013 Mar; 25(2):166-72. PubMed ID: 23299197
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4.
    Klein O; Ebert LM; Nicholaou T; Browning J; Russell SE; Zuber M; Jackson HM; Dimopoulos N; Tan BS; Hoos A; Luescher IF; Davis ID; Chen W; Cebon J
    Clin Cancer Res; 2009 Apr; 15(7):2507-13. PubMed ID: 19318477
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient responses to ipilimumab, a novel immunopotentiator for metastatic melanoma: how different are these from conventional treatment responses?
    Pennock GK; Waterfield W; Wolchok JD
    Am J Clin Oncol; 2012 Dec; 35(6):606-11. PubMed ID: 21336089
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ipilimumab: a promising immunotherapy for melanoma.
    Thumar JR; Kluger HM
    Oncology (Williston Park); 2010 Dec; 24(14):1280-8. PubMed ID: 21294471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ipilimumab in advanced melanoma: reports of long-lasting responses.
    Farolfi A; Ridolfi L; Guidoboni M; Nicoletti SV; Piciucchi S; Valmorri L; Costantini M; Scarpi E; Amadori D; Ridolfi R
    Melanoma Res; 2012 Jun; 22(3):263-70. PubMed ID: 22516968
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical development of the anti-CTLA-4 antibody tremelimumab.
    Ribas A
    Semin Oncol; 2010 Oct; 37(5):450-4. PubMed ID: 21074059
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment.
    Fong L; Small EJ
    J Clin Oncol; 2008 Nov; 26(32):5275-83. PubMed ID: 18838703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab (MDX-010), a novel treatment strategy in cancer management.
    Movva S; Verschraegen C
    Expert Opin Biol Ther; 2009 Feb; 9(2):231-41. PubMed ID: 19236253
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues.
    Phan GQ; Weber JS; Sondak VK
    Ann Surg Oncol; 2008 Nov; 15(11):3014-21. PubMed ID: 18716842
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ipilimumab (Yervoy) and the TGN1412 catastrophe.
    Bakacs T; Mehrishi JN; Moss RW
    Immunobiology; 2012 Jun; 217(6):583-9. PubMed ID: 21821307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies.
    O'Day SJ; Hamid O; Urba WJ
    Cancer; 2007 Dec; 110(12):2614-27. PubMed ID: 18000991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intralesional and systemic immunotherapy for metastatic melanoma.
    Luu C; Khushalani NI; Zager JS
    Expert Opin Biol Ther; 2016 Dec; 16(12):1491-1499. PubMed ID: 27602429
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ipilimumab targeting CD28-CTLA-4 axis: new hope in the treatment of melanoma.
    Lens M; Testori A; Ferucci PF
    Curr Top Med Chem; 2012; 12(1):61-6. PubMed ID: 22196270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network.
    Voskens CJ; Goldinger SM; Loquai C; Robert C; Kaehler KC; Berking C; Bergmann T; Bockmeyer CL; Eigentler T; Fluck M; Garbe C; Gutzmer R; Grabbe S; Hauschild A; Hein R; Hundorfean G; Justich A; Keller U; Klein C; Mateus C; Mohr P; Paetzold S; Satzger I; Schadendorf D; Schlaeppi M; Schuler G; Schuler-Thurner B; Trefzer U; Ulrich J; Vaubel J; von Moos R; Weder P; Wilhelm T; Göppner D; Dummer R; Heinzerling LM
    PLoS One; 2013; 8(1):e53745. PubMed ID: 23341990
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management.
    Savoia P; Astrua C; Fava P
    Hum Vaccin Immunother; 2016 May; 12(5):1092-101. PubMed ID: 26889818
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The ipilimumab lesson in melanoma: achieving long-term survival.
    Delyon J; Maio M; Lebbé C
    Semin Oncol; 2015 Jun; 42(3):387-401. PubMed ID: 25965357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Anti-CTLA-4 monoclonal antibody: a major step in the treatment of metastatic melanoma].
    Robert C; Mateus C
    Med Sci (Paris); 2011 Oct; 27(10):850-8. PubMed ID: 22027422
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ipilimumab for advanced melanoma: a nursing perspective.
    Ledezma B
    Oncol Nurs Forum; 2009 Jan; 36(1):97-104. PubMed ID: 19136343
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Orbital myositis associated with ipilimumab].
    Lecouflet M; Verschoore M; Giard C; Gohier P; Le Corre Y; Milea D; Martin L
    Ann Dermatol Venereol; 2013; 140(6-7):448-51. PubMed ID: 23773743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.